HK1211302A1 - 抗體及其用途 - Google Patents
抗體及其用途Info
- Publication number
- HK1211302A1 HK1211302A1 HK15112087.2A HK15112087A HK1211302A1 HK 1211302 A1 HK1211302 A1 HK 1211302A1 HK 15112087 A HK15112087 A HK 15112087A HK 1211302 A1 HK1211302 A1 HK 1211302A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- asgpr
- antibodies
- asgpr antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261681239P | 2012-08-09 | 2012-08-09 | |
PCT/EP2013/066432 WO2014023709A1 (en) | 2012-08-09 | 2013-08-06 | Asgpr antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1211302A1 true HK1211302A1 (zh) | 2016-05-20 |
Family
ID=48917550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15112087.2A HK1211302A1 (zh) | 2012-08-09 | 2015-12-08 | 抗體及其用途 |
Country Status (11)
Country | Link |
---|---|
US (5) | US9771427B2 (zh) |
EP (1) | EP2882775B1 (zh) |
JP (3) | JP2015525792A (zh) |
KR (1) | KR20150041626A (zh) |
CN (2) | CN109705218B (zh) |
BR (1) | BR112015002790A2 (zh) |
CA (1) | CA2878626A1 (zh) |
HK (1) | HK1211302A1 (zh) |
MX (1) | MX2015001678A (zh) |
RU (1) | RU2015107891A (zh) |
WO (1) | WO2014023709A1 (zh) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9518087B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
RU2015107891A (ru) | 2012-08-09 | 2016-09-27 | Роше Гликарт Аг | Антитела к asgpr и их применения |
SI3043776T1 (sl) | 2013-09-11 | 2024-03-29 | Eagle Biologics, Inc. | Tekoče proteinske formulacije, ki vsebujejo vodotopna organska barvila |
SG10202010936RA (en) * | 2014-02-21 | 2020-12-30 | Ecole Polytecnique Fed De Lausanne Epfl Epfl Tto | Glycotargeting therapeutics |
US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10993990B2 (en) | 2014-05-16 | 2021-05-04 | Baylor Research Institute | Methods and compositions for treating autoimmune and inflammatory conditions |
EP3200804A4 (en) | 2014-10-01 | 2018-04-18 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
US10501546B2 (en) | 2015-09-04 | 2019-12-10 | The California Institute For Biomedical Research | Insulin immunoglobulin fusion proteins |
AU2016325073B2 (en) * | 2015-09-19 | 2023-03-16 | Ecole Polytechnique Federale De Lausanne (Epfl) | Glycotargeting therapeutics |
AU2016332900C1 (en) * | 2015-09-29 | 2024-02-01 | Amgen Inc. | ASGR inhibitors |
EP3574019A4 (en) | 2017-01-26 | 2021-03-03 | Surrozen, Inc. | TISSUE SPECIFIC, WNT SIGNAL REINFORCEMENT MOLECULES AND USES THEREOF |
EP3638296A1 (en) | 2017-06-16 | 2020-04-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
CA3066945A1 (en) | 2017-06-27 | 2019-01-03 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized asgr1 locus |
WO2020014271A1 (en) * | 2018-07-09 | 2020-01-16 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses |
JP7479383B2 (ja) | 2018-09-27 | 2024-05-08 | エクシリオ デベロップメント, インコーポレイテッド | マスクされたサイトカインポリペプチド |
KR20220012227A (ko) * | 2019-03-28 | 2022-02-03 | 오리오니스 바이오사이언시즈 인코포레이티드 | Clec9a-기반 키메라 단백질 복합체 |
WO2021072203A1 (en) | 2019-10-09 | 2021-04-15 | Silverback Therapeutics, Inc. | Tgfbetar1 inhibitor-asgr antibody conjugates and uses thereof |
KR102269748B1 (ko) | 2019-10-31 | 2021-06-29 | 주식회사 에이스바이오메드 | 간세포 손상 표지자 아시알로 알파-1산 당단백질 측정을 통한 진행성 만성간염 및 간섬유화 정도 추적 진단용 키트 및 이의 용도 |
AU2021245922A1 (en) * | 2020-04-01 | 2022-10-13 | Xilio Development, Inc. | Masked IL-2 cytokines and their cleavage products |
MX2022016588A (es) * | 2020-06-23 | 2023-03-15 | Kadmon Corp Llc | Anticuerpos anti-pd-1 y proteinas de fusion. |
CA3183993A1 (en) | 2020-07-01 | 2022-01-06 | Peter R. Baum | Anti-asgr1 antibody conjugates and uses thereof |
TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
WO2022087458A1 (en) * | 2020-10-23 | 2022-04-28 | Asher Biotherapeutics, Inc. | Fusions with cd8 antigen binding molecules for modulating immune cell function |
TW202233656A (zh) * | 2020-11-16 | 2022-09-01 | 美商蘇羅森營運公司 | 肝特異性wnt訊號增強分子及其用途 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR7801185A (pt) | 1977-04-18 | 1978-11-28 | Hitachi Metals Ltd | Ornato adaptado para ser fixado por pelo menos um ima permanente |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DE69233254T2 (de) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanisierter Heregulin Antikörper |
KR950014915B1 (ko) * | 1991-06-19 | 1995-12-18 | 주식회사녹십자 | 탈시알로당단백-포함화합물 |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
WO2005097832A2 (en) | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
NZ549872A (en) | 2004-04-13 | 2009-09-25 | Hoffmann La Roche | Anti-P-selectin antibodies |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
EP2235064B1 (en) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
EP2467165B1 (en) | 2009-08-17 | 2015-01-07 | Roche Glycart AG | Targeted immunoconjugates |
JP2013516967A (ja) | 2010-01-14 | 2013-05-16 | グラクソ グループ リミテッド | 肝臓標的化ドメイン抗体 |
RU2015107891A (ru) | 2012-08-09 | 2016-09-27 | Роше Гликарт Аг | Антитела к asgpr и их применения |
-
2013
- 2013-08-06 RU RU2015107891A patent/RU2015107891A/ru not_active Application Discontinuation
- 2013-08-06 MX MX2015001678A patent/MX2015001678A/es unknown
- 2013-08-06 BR BR112015002790A patent/BR112015002790A2/pt not_active IP Right Cessation
- 2013-08-06 KR KR20157003176A patent/KR20150041626A/ko not_active Application Discontinuation
- 2013-08-06 EP EP13745419.5A patent/EP2882775B1/en active Active
- 2013-08-06 CN CN201910108288.7A patent/CN109705218B/zh active Active
- 2013-08-06 JP JP2015525859A patent/JP2015525792A/ja not_active Ceased
- 2013-08-06 WO PCT/EP2013/066432 patent/WO2014023709A1/en active Application Filing
- 2013-08-06 CA CA2878626A patent/CA2878626A1/en not_active Abandoned
- 2013-08-06 US US14/419,824 patent/US9771427B2/en active Active
- 2013-08-06 CN CN201380041685.8A patent/CN104704001B/zh active Active
-
2015
- 2015-12-08 HK HK15112087.2A patent/HK1211302A1/zh unknown
-
2017
- 2017-09-21 US US15/711,495 patent/US10087254B2/en active Active - Reinstated
-
2018
- 2018-01-23 JP JP2018008673A patent/JP6463522B2/ja active Active
- 2018-09-14 US US16/131,110 patent/US20190031760A1/en not_active Abandoned
- 2018-12-28 JP JP2018247659A patent/JP6929827B2/ja active Active
-
2019
- 2019-08-09 US US16/537,038 patent/US10975151B2/en active Active
-
2020
- 2020-11-23 US US17/102,112 patent/US20210324085A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2015107891A (ru) | 2016-09-27 |
MX2015001678A (es) | 2015-08-14 |
KR20150041626A (ko) | 2015-04-16 |
US20200102392A1 (en) | 2020-04-02 |
CA2878626A1 (en) | 2014-02-13 |
BR112015002790A2 (pt) | 2017-08-08 |
CN104704001A (zh) | 2015-06-10 |
EP2882775A1 (en) | 2015-06-17 |
US20150299324A1 (en) | 2015-10-22 |
JP6463522B2 (ja) | 2019-02-06 |
JP2018093880A (ja) | 2018-06-21 |
JP6929827B2 (ja) | 2021-09-01 |
WO2014023709A1 (en) | 2014-02-13 |
JP2019088290A (ja) | 2019-06-13 |
EP2882775B1 (en) | 2018-02-14 |
CN109705218A (zh) | 2019-05-03 |
CN109705218B (zh) | 2022-07-19 |
US20190031760A1 (en) | 2019-01-31 |
US9771427B2 (en) | 2017-09-26 |
JP2015525792A (ja) | 2015-09-07 |
US10087254B2 (en) | 2018-10-02 |
US10975151B2 (en) | 2021-04-13 |
US20210324085A1 (en) | 2021-10-21 |
CN104704001B (zh) | 2019-02-12 |
US20180118833A1 (en) | 2018-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1211302A1 (zh) | 抗體及其用途 | |
HK1207092A1 (zh) | 抗- 抗體及其用途 | |
HK1214282A1 (zh) | 抗- 抗體及抗體-藥物綴合物 | |
HRP20190358T1 (hr) | Antitijela protiv asic1 i njihova primjena | |
IL238559A0 (en) | Antibodies against ceacam5 and their use | |
EP2879708A4 (en) | ANTIBODY AND ANTI-ETBR IMMUNOCONJUGATES | |
HK1210714A1 (zh) | 抗體製劑及其用途 | |
HK1205523A1 (zh) | 抗-大-內皮素- 抗體及其用途 | |
HUE037613T2 (hu) | Anti-TLR4 antitestek és azok felhasználása | |
EP2879711A4 (en) | ANTI-ETBR ANTIBODIES AND IMMUNOCONJUGATES | |
GB201208372D0 (en) | Antibodies and uses thereof |